Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.

ABSTRACT:

Purpose

We examined the characteristics of breast cancer patients with oligometastases (OM) treated with stereotactic ablative body radiotherapy (SABR) to identify factors associated with local progression, distant metastasis progression, time to subsequent therapy, progression-free survival (PFS), and overall survival (OS).

Methods

We retrospectively reviewed a single-institution database of patients treated with radiotherapy between 2008 and 2018 and identified 79 patients who received SABR to OM. Twenty-seven patients had genetic testing of metastatic tumors using an institutional targeted sequencing platform. Kaplan-Meier analysis, Cox regression, and competing risk models were used to compare clinical and genetic correlates with outcomes.

Results

Median follow-up

SUBMITTER: Wijetunga NA 

PROVIDER: S-EPMC8335830 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature